Verastem (VSTM) Net Income towards Common Stockholders Growth (3y) (2014 - 2026)
Verastem (VSTM) Net Income towards Common Stockholders Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 45.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 91.31% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Verastem | 607.94 Mn | 410.11 Mn | 15.90 Mn | -32.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.44% |
| Dec 31, 2025 | 29.87% |
| Sep 30, 2025 | -34.57% |
| Jun 30, 2025 | -34.94% |
| Mar 31, 2025 | -37.21% |
| Dec 31, 2024 | -24.71% |
| Sep 30, 2024 | -14.40% |
| Jun 30, 2024 | 19.08% |
| Mar 31, 2024 | -16.49% |
| Dec 31, 2023 | -14.61% |
| Sep 30, 2023 | -52.36% |
| Jun 30, 2023 | 4.11% |
| Mar 31, 2023 | 20.43% |
| Dec 31, 2022 | 23.91% |
| Sep 30, 2022 | 15.52% |
| Jun 30, 2022 | 19.56% |
| Mar 31, 2022 | 23.30% |
| Dec 31, 2021 | 23.56% |
| Sep 30, 2021 | 24.47% |
| Jun 30, 2021 | 12.91% |